Utah-based Civica will begin selling a type of long-acting insulin on Jan. 1, 2026, although it will not come from the nonprofit drug maker’s Petersburg facility. Civica announced Thursday it has ...
Civica Rx is a nonprofit generic drug company created in 2018 by seven major health systems to combat drug shortages and rising drug costs. In just over a year, the company has created partnerships ...
Non-profit drugmaker Civica Rx has said it will launch biosimilars of three big-selling insulin products in the US by 2024 to help diabetic patients struggling with the cost of the drugs. First ...
Civica plans to distribute its insulin glargine to pharmacies across the United States for $45 for a box of five pens. “Through the partnership we formed with Civica more than six years ago, BCBSA and ...
PETERSBURG — Civica Inc. has announced plans to use its Petersburg facility to manufacture and distribute insulins to its hospital partners across the United States. Once approved, these new insulins ...
CivicaScript's first product is hitting the market. The public benefits company and sister to Civica Rx is making its first generic available: 250-mg abiraterone acetate tablets. The drug is used in ...
In a move aimed at expanding affordable treatment options for millions of Americans living with diabetes, Biocon Biologics Ltd. and nonprofit generic drug manufacturer Civica, Inc. have announced a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results